TSTickerStarGet alerts

JAGX 10-Q filed 2026-11-16 | Key takeaways

JAGX filed its 10-Q; the most relevant disclosure change is expanded Customer concentration: For the three and nine months ended September 30, 2026, approximately 98% of the Company's revenue was derived from Woodward Specialty LLC. Customer 1 accounted for 98% of Q3 2026 revenue, 0% of Q3 2025 revenue; Customer 2 accounted for 0% of Q3 2026 revenue v. Customer concentration: Woodward Specialty LLC (Customer 1) represented 98% of revenue; Customer 2 (formerly specialty pharmacies for Mytesi) represented 0% of re...

Share this story

Key takeaways

  • Customer concentration: Woodward Specialty LLC accounted for 98% of both Q3 and nine-month 2026 revenue, compared to 0% in the prior-year periods when Mytesi sales to specialty pharmacies were the primary revenue source.

  • Share count explosion: The Series R Preferred Stock dividend (paid October 15, 2026) and automatic conversion on November 2, 2026 resulted in approximately 13.3 million shares outstanding, nearly six times the 2.1 million shares outstanding at September 30, 2026.

  • Going concern: The company states it does not have cash balances sufficient to fund its operating plan through one year from issuance, with an accumulated deficit of $409.5 million as of September 30, 2026.

  • Notes payable reduction: Total current notes payable decreased to $2.5 million (net of discount) from $27.4 million at December 31, 2025, primarily due to debt extinguishment transactions including exchanges for common stock.

  • Series P and Q preferred stock: New designations appeared with 240 shares of Series P non-convertible preferred and 868 shares of Series Q perpetual preferred outstanding at September 30, 2026.

Key metrics

Total revenue, net (Q3)Q3 2026 (three months ended September 30, 2026)
$2.343 million-24.0% from $3.083 million
Total revenue, net (9-month)Nine months ended September 30, 2026
$23.840 million+188.1% from $8.276 million
License revenue (Q3)Q3 2026
$1.792 million+4,167% from $42 thousand
Product revenue, net (Q3)Q3 2026
$551 thousand-81.9% from $3.041 million
Net loss (Q3)Q3 2026
($5.830 million)Improved from ($9.648 million)
Net loss (9-month)Nine months ended September 30, 2026
($9.909 million)Improved from ($30.804 million)
Net loss per share, basic and diluted (Q3)Q3 2026
($9.23)Improved from ($2,032.95) due to reverse stock splits and increased share count
Shares outstandingAs of November 13, 2026 (post-Series R conversion)
13,345,986 sharesNearly 6x increase from approximately 2.1 million shares at September 30, 2026

Customer concentration

Woodward Specialty LLC (Customer 1)Q3 2026 and nine months ended September 30, 2026
98%Share of revenue
Customer 2 (formerly specialty pharmacies for Mytesi)Q3 2026 and nine months ended September 30, 2026
0%Share of revenue
Customer 3Q3 2026 and nine months ended September 30, 2026
2%Share of revenue
Woodward Specialty LLC (Customer 1)September 30, 2026
100%Share of accounts receivable

Disclosure changes

  • Customer concentration

    For the three and nine months ended September 30, 2026, approximately 98% of the Company's revenue was derived from Woodward Specialty LLC. Customer 1 accounted for 98% of Q3 2026 revenue, 0% of Q3 2025 revenue; Customer 2 accounted for 0% of Q3 2026 revenue versus 55% in Q3 2025.

    The concentration increased to 98% and the company moved from a multi-customer product revenue model to a single-customer license revenue model, creating significant revenue concentration risk.
  • Subsequent events - Series R Preferred Stock dividend and conversion

    On October 2, 2026, the Company declared a special one-time dividend of one share of Series R Preferred Stock for each share of common stock outstanding, plus shares issuable upon exercise of certain warrants and pre-funded warrants; paid on October 15, 2026. On November 2, 2026, each share of Series R Preferred Stock automatically converted into five shares of common stock, resulting in approximately 13,345,986 shares outstanding (nearly 6x pre-conversion count).

    Massive dilution event: share count increased from approximately 2.1 million pre-conversion to 13.3 million post-conversion, significantly impacting per-share metrics and existing shareholder ownership percentages.
  • Reverse stock splits

    The company executed a 1-for-35 reverse stock split effective April 30, 2026, and a 1-for-15 reverse stock split effective September 17, 2026. These reverse splits are reflected in the share counts presented.

    Multiple reverse stock splits in 2026 significantly increased per-share metrics while reducing outstanding shares, affecting historical comparability of share-based metrics.
  • Preferred stock - new series designations

    As of September 30, 2026: Series P non-convertible preferred stock (300 shares designated, 240 shares outstanding); Series Q perpetual preferred stock (2,000 shares designated, 868 shares outstanding); Series L and M perpetual preferred stock decreased to 0 shares outstanding from 121 and 144 respectively at December 31, 2025.

    Changes in preferred stock structure affect equity treatment, dividend obligations, and potential conversion/dilution impacts.
  • Notes payable reduction

    Notes payable, net of discount decreased to $2.5 million as of September 30, 2026, from $27.4 million at December 31, 2025. The Fair Value Option designated portion decreased from $26.2 million to $2.2 million.

    Significant reduction in debt obligations through debt extinguishment transactions, partially offset by share issuance dilution.
  • Liquidity and going concern

    The company states it does not have cash balances sufficient to fund its operating plan through one year from the issuance date. Accumulated deficit increased to $409.5 million from $403.7 million at June 30, 2026 and $399.9 million at December 31, 2025. The company entered into a license and supply agreement in January 2026 providing $16.0 million upfront revenue (plus $3.0 million fee), but still needs additional funding.

    The company continues to face substantial doubt about its ability to continue as a going concern, requiring ongoing financing to fund operations.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow JAGX in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert